Robust and reproducible population receptive field mapping in patients with retinal pathologies - Takeaways - MDSpire

Robust and reproducible population receptive field mapping in patients with retinal pathologies

  • By

  • Maximilian Pawloff

  • David Linhardt

  • Michael Woletz

  • Marlene Hollaus

  • Georgios Mylonas

  • Graham E. Holder

  • Stefan Sacu

  • Christian Windischberger

  • Markus Ritter

  • June 4, 2026

  • 0 min

Share

  • 1

    The study investigates the reproducibility of population receptive field mapping using 7 Tesla fMRI in patients with Stargardt disease and geographic atrophy.

  • 2

    Participants included eleven patients with Stargardt disease and eleven with geographic atrophy, all confirmed by genetic testing and optical coherence tomography.

  • 3

    Both intrasession and intersession reproducibility of pRF mapping results were assessed to understand cortical representation of central retinal scotomata.

  • 4

    Functional MRI measurements were conducted on a Siemens MAGNETOM 7 T scanner, allowing for high-resolution activation maps of the visual cortex.

  • 5

    Previous studies indicated that fMRI-derived cortical silent zones correspond closely to visual field defects in patients with retinal pathology.

Original Source(s)

Robust and reproducible population receptive field mapping in patients with retinal pathologies

  • by Maximilian Pawloff, David Linhardt, Michael Woletz, Marlene Hollaus, Georgios Mylonas, Graham E. Holder, Stefan Sacu, Christian Windischberger, Markus Ritter

  • June 4, 2026

Related Content

FDA Monthly Preview: Key May Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

Could Red-Light Therapy Change Myopia Care? 

Across 28 trials, pediatric patients receiving therapy had less myopia progression over 12 months, though long-term risks remain under study.

Diabetic Retinal Disease Rates Narrow by Diabetes Type

US claims data showed rising prevalence of diabetic retinal disease in type 1 and type 2 diabetes, while incidence declined in type 1 diabetes and moved closer to type 2 rates by 2022.